ClinicalTrials.gg
TerminatedNCT00325650RAPSODIUpdated May 18, 2016

Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes

A Phase 3 interventional study of Rimonabant and Placebo (for Rimonabant) in Prediabetic State, sponsored by Sanofi. Terminated at 1 site in United States. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-05-18.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was terminated
Company decision taken in light of demands by certain national health authorities

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,420
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 390 studies in Prediabetic State with a site in United States — 83 open to participants now, 107 under way, 2 of them phase 3. Prediabetic State · United States.

Enrollment
8th of 362
2,420 · median 54
Started
2006
with 5 others
Phase 3
16 of 390
2 open now
Registered
9th of 390
by date

Among the 390 studies in Prediabetic State with a site in United States, this one is the 8th largest by enrollment of the 362 interventional ones that give a count, is one of 6 that started in 2006, is one of 16 in phase 3, and was the 9th registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

83 of the 390 studies in Prediabetic State with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 390 studies in Prediabetic State with a site in United States, or all of them as a file.
02

Study summary

Primary objective:

To evaluate the effect of long-term administration of Rimonabant on the time of progression to type 2 diabetes in patients with prediabetes (i.e. Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT) or both at baseline).

Secondary objectives:

  • To assess the effect on weight loss and weight maintenance; sustained effect following a washout period, effect on other markers of glycemic control (fasting glucose, fasting-insulin and HbA1c), glucose tolerance and insulin responses during oral glucose tolerance tests (OGTTs), and on other risk factors (HDL-Cholesterol, TG),
  • To assess the effect on quality of life
  • To evaluate long term safety and tolerability.
Read the detailed description

The total duration per patient will be approximately 38 months including a 30-month double-blind treatment period.

03

Conditions studied

  • Prediabetic State

Keywords

  • Prediabetic state
  • Impaired fasting glucose
  • Impaired glucose Tolerance
04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No previous history of treatment for type 2 diabetes.
  • Diagnosis of :

    • Impaired Glucose Tolerance (IGT) based on one oral glucose tolerance test (OGTT) and defined as a 2 hour post-challenge glucose (after a 75-g Oral Glucose Tolerance Test) > 140 mg/dL (7.8 mmol/L) but \< 200 mg/dL (11.1 mmol/L), at the screening visit.
    • And / or impaired fasting glucose (IFG) based on a Fasting Plasma Glucose (FPG) ³ 100 mg/dL (5.6 mmol/L) and \< 126 mg/dL (7.0 mmol/L), at the screening visit.

Exclusion criteria

Exclusion Criteria:

  • Absence of effective method for females of .
  • Presence of any endocrine disease according to the Investigator.Note: euthyroid patients on replacement therapy will be included if the dosage of thyroxine is stable for at least 3 months prior to screening visit.
  • Presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the patient's safety or successful participation in the study.
  • Presence or history of cancer within the past five years with the exception of adequately treated localized basal cell skin cancer or in situ uterine cervical cancer.
  • Related to laboratory findings:

    • positive test for surface antigen and/or antibody;
    • Positive urine pregnancy test in females of childbearing potential ;
    • Thyroid-stimulating hormone (TSH) and free T4 outside central laboratory normal range.
  • Related to previous or concomitant medications:

    • Within 3 months prior to screening visit and/or during the screening period:

      • anti-obesity drugs (e.g., sibutramine, orlistat, herbal preparations, etc),
      • systemic long-acting ; prolonged use (more than 10 days) of systemic corticosteroids;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,420 participants (actual)

Study arms

  • Experimental
    Rimonabant

    Rimonabant 20 mg once daily

    Drug: Rimonabant

  • Placebo comparator
    Placebo

    Placebo (for Rimonabant) once daily.

    Drug: Placebo (for Rimonabant)

Interventions

  • Tablet, oral administration

    Also known as: SR141716, Acomplia

  • DrugPlacebo (for Rimonabant)

    Tablet, oral administration

06

What researchers measure

Primary outcomes

  1. Time of progression to type 2 diabetes

    Time frame: Baseline to 30 months

Secondary outcomes

  1. Change from baseline in body weight

    Time frame: Baseline to 30 months

  2. Change from baseline in waist circumference

    Time frame: Baseline to 30 months

  3. Change from baseline in in glucose homeostasis (HbA1C, fasting plasma glucose and fasting insulin)

    Time frame: Baseline to 30 months

  4. Change from baseline in glucose and insulin at 2 hour post-glucose load

    Time frame: Baseline to 30 months

  5. Change from baseline in HDL-Cholesterol and triglycerides (TG)

    Time frame: Baseline to 30 months

07

Study locations

1 site
  • Sanofi-Aventis
    Bridgewater, New Jersey 08807, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2006
First posted
May 15, 2006
Start
May 2006
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results delay requested
Apr 19, 2016
Last update
May 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00325650
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 15, 2006
Start date
May 2006
Primary completion
Mar 2009
Completion
Mar 2009
Last update
May 18, 2016

Study contacts

ICD CSD
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimonabant

Start the discussion